Novo Nordisk’s chief financial officer, Mike Doustdar, has indicated that the company remains active in pursuing strategic acquisitions despite losing out to Pfizer in a recent $10 billion takeover bid for obesity drug developer Metsera. The failed contest underscores the intense competition among major pharmaceutical firms to secure footholds in the lucrative weight-loss market driven by growing demand for obesity treatments.
While Novo Nordisk did not succeed in acquiring Metsera, the company continues to assess potential deals to strengthen its position in the sector. Industry analysts note that the weight-loss and diabetes markets are experiencing rapid growth, prompting companies like Novo Nordisk to seek innovative therapies and expand their portfolios through acquisitions and collaborations.
Pfizer’s successful bid for Metsera may reshape competitive dynamics within the industry, but Novo Nordisk remains committed to strategic growth opportunities. The company has emphasized its ongoing focus on research, development, and potential acquisitions to regain momentum and capitalize on the expanding global demand for obesity and metabolic disorder treatments.